Trial Profile
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ATLAS
- 12 Dec 2023 Results assessing HRQoL in Polish patients with multiple myeloma treated in this study, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of detailed analysis of minimal residual negative disease (MRD) at multiple timepoints presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing residual disease and its prognostic performance compared to routine MRD assessments, presented at the 65th American Society of Hematology Annual Meeting and Exposition.